Kiniksa (KNSA) PT Raised to $44 at JMP Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Kiniksa Presents KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology
September 15, 2018 8:00 AM EDT- Single-doses were well-tolerated and showed reduction in pruritus -
- Data support plans for advancement into multiple chronic pruritic diseases, including prurigo nodularis -
HAMILTON, BERMUDA, Sept. 15, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today presented... More
Kiniksa Presents KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology
September 15, 2018 8:00 AM EDT- Single-doses were well-tolerated and showed reduction in pruritus -
- Data support plans for advancement into multiple chronic pruritic diseases, including prurigo nodularis -
HAMILTON, BERMUDA, Sept. 15, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today presented Phase 1a/1b... More
